Effects of losartan on urinary secretion of extracellular matrix and their modulators in type 2 diabetes mellitus patients with microalbuminuria

Clinical and Investigative Medicine

Volumn 29, Issue 6, 2006, Pages 365-372

  Woo, Vincent ^a   Ni, Lian Song ^a   Hak, Dixie ^a   Berard, Lori ^a   Zhu, Fuqin ^a   Khan, Shagufta ^a   Ma, Guoping M ^a   Penner, Brian ^a   Shen, Garry X ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN TYPE 4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC FACTOR; FIBRONECTIN; GLIBENCLAMIDE; INSULIN; LOSARTAN; METFORMIN; TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; UROKINASE;

ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY FUNCTION; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; URINARY EXCRETION;

ADULT; AGED; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD COAGULATION FACTORS; BLOOD PRESSURE; CHOLESTEROL; COLLAGEN TYPE IV; CREATINE; DIABETES MELLITUS, TYPE 2; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBRONECTINS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; LOSARTAN; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; POTASSIUM; REGRESSION ANALYSIS; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 33847715183     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14 Suppl 5:S1-85
2. US Renal Data System: USRDS 2002 Annual Data Report. Atlas of end-stage renal disease in the United States. Besthesda MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease. www.usrds.org/adr_2002.htm
3. Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999;55:1-28
4. Brenner BM, Cooper ME, de Zeeuw D, et al. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
5. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
6. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
7. Wogensen L, Krag S, Chai Q, Ledet T. The use of transgenic animals in the study of diabetic kidney disease. Horm Metab Res 2005;37 Suppl 1:17-25
8. Mauviel A. Transforming growth factor-beta: a key mediator of fibrosis. Methods Mol Med 2005;117:69-80
9. Esmatjes E, Flores L, Inigo P, Lario S, Ruilope LM, Campistol JM. Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 2001;16 Suppl 1:90-3
10. Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 2002;25:1072-7
11. Nishimura M, Sasaki T, Ohishi A, et al. Angiotensin-converting enzyme inhibitors and probucol suppress the time-dependent increase in urinary Type IV collagen excretion of Type II diabetes mellitus patients with early diabetic nephropathy. Clin Nephrol 2001;56:96-103
12. Murayama S, Hirano T, Sakaue T, Okada K, Ikejiri R, Adachi M. Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. Hypertens Res 2003;26:453-8
13. Tada H, Tsukamoto M, Ishii H, Isogai S. A high concentration of glucose alters the production of tPA, uPA and PAI-1 antigens from human mesangial cells. Diabetes Res Clin Pract 1994;24:33-9
14. Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000;58:251-9
15. WHO Expert Committee on Diabetes Mellitus. Second report. World Health Organ Tech Rep Ser 1980;646:1-80
16. Zhang J, Ren S, Sun D, Shen GX. Influence of glycation on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells. Arterioscler Thromb Vasc Biol 1998;18:1140-8
17. Jones CL, Buch S, Post M, McCulloch L, Liu E, Eddy AA. Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats. Am J Pathol 1192;141:1381-96
18. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000;35:695-707
19. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317(7160):713-20
20. Fogari R, Zoppi A, Corradi L, et al. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1999;13:47-53
21. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997;46:1182-8
22. Viberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8
23. Davis BJ, Cao Z, de Gasparo M, Kawachi H, Cooper ME, Allen TJ. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. J Hypertens 2003;21:209-16
24. Wang SN, LaPage J, Hirschberg R. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney Int 2000;57:1002-14
25. Wolf G. Link between angiotensin II and TGF-beta in the kidney. Miner Electrolyte Metab 1998;24:174-80
26. Perlman A, Lawsin LM, Kolachana P, Saji M, Moore J Jr, Ringel MD. Angiotensin II regulation of TGF-beta in marine mesangial cells involves both PI3 kinase and MAP kinase. Ann Clin Lab Sci 2004;34:277-86
27. Eikmans M, Baelde HJ, Hagen EC, et al. Renal mRNA levels as prognostic tools in kidney diseases. J Am Soc Nephrol 2003;14:899-907
28. Cha DR, Kim IS, Kang YS, et al. Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with Type 2 diabetes mellitus. Diabet Med 2005;22:14-20
29. Ha SW, Kim HJ, Bae JS,et al. Concentration of urinary betaig-h3, transforming growth factor-beta-induced protein in patients with type 2 diabetes and nephropathy. Diabetes Res Clin Pract 2004;65:167-73
30. Erdem Y, Usalan C, Haznedaroglu IC,et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999;12:1071-6
31. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999;34:285-90
32. Fogari R, Mugellini A, Zoppi A, et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002;15:316-20
33. Gesualdo L, Ranieri E, Monno R, et al. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney Int 1999;56:461-70
34. Kerins DM, Hao Q, Vaughan DE. Comparative effect of angiotensin- converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999;34:285-90
35. Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 2000;58:1841-50
36. Nicholas SB, Aguiniga E, Ren Y, et al. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 2005;67:1297-307